The importance of inflammatory response mediators in the mechanisms of atherogenesis and their effect on the results of myocardial revascularization in patients with coronary artery disease
Authors:
Company: Bakoulev National Medical Research Center for Cardiovascular Surgery, Moscow, Russian Federation
For correspondence: Sign in or register.
Type: Reviews
DOI:
For citation: Iraskhanov A.Sh., Buziashvili Yu.I., Koksheneva I.V., Tugeeva E.F., Timerbulatova T.R. The importance of inflammatory response mediators in the mechanisms of atherogenesis and their effect on the results of myocardial revascularization in patients with coronary artery disease. Creative Cardiology. 2023; 17 (3): 330–40 (in Russ.). DOI: 10.24022/1997-3187-2023-17-3-330-340
Received / Accepted: 25.08.2023 / 28.09.2023
Keywords: сoronary artery bypass grafting coronary artery disease coronary bypass dysfunction thrombosis atherosclerosis systemic inflammation response syndrome systemic inflammation
Abstract
Aorto-coronary bypass surgery (CABG) is widely used in clinical practice and is one of the most studied methods of surgical intervention. This type of myocardial revascularization is considered more effective than endovascular interventions. It is known that activation of a systemic inflammatory response leads to the development of cardiovascular complications (nonfatal myocardial infarction, stroke, death). One of the most common complications in the early postoperative period after CABG is the dysfunction of coronary graft (DCG). It is assumed that activation of systemic inflammatory response plays an important role in the development of graft dysfunction both in the early and late postoperative period. The study of the pathophysiological mechanisms underlying the development of cardiovascular complications, as well as the identification of new biomarkers and therapeutic strategies for their prevention are important trends today. This article discusses the role of various markers of inflammation in the development of cardiovascular events.References
- Karpov Yu.A., Kukharchuk V.V., Lyakishev A. Diagnosis and treatment of chronic ischemic heart disease. Practical advice. Cardiological Bulletin. 2015; 3: 3–33 (in Russ.).
- Knuuti J., Wijns W., Saraste A. ESC guidelines on the diagnosis and management of chronic coronary syndromes: the task force for diagnosis and management of chronic coronary syndromes of the European society of cardiology (ESC) Eur. Heart J. 2020; 41: 407–77. DOI: 10.1093/eurheartj/ehz425
- Sokolova N.Yu., Golukhova E.Z. Myocardial revascularization in patients with stable coronary artery disease: the stratification of perioperative and long-term risks. A.N. Bakoulev Scientific Center for Cardiovascular Surgery of Ministry of Health of the Russian Federation (in Russ.). DOI: 10.15275/kreatkard.2016.01.03
- Ţintoiu I.C., Bontaş E., Cristian G., Mocanu I., Călinescu F.B., Kibos A.S. Current risk scores for the establishment of the best myocardial revascularization methods. In: Ţintoiu I., Underwood M., Cook S., Kitabata H., Abbas A. (Eds.) Coronary Graft Failure. Springer; Cham: 2016. DOI: 10.1007/978-3-319-26515-5_10
- De Vries M.R., Simons K.H., Jukema J.W., Braun J., Quax P.H. Vein graft failure: from pathophysiology to clinical outcomes. Nat. Rev. Cardiol. 2016; 13 (8): 451–70. DOI: 10.1038/nrcardio.2016.76
- Fan F., Ai Y., Sun T., Li S., Liu H., Shi X., Cheng Y. The role of inflammatory cytokines in anemia and gastrointestinal mucosal injury induced by foot electric stimulation. Scientific Reports, 2021; 11 (1): 1–9. DOI: 10.1038/s41598-021-82604-7
- Duan H.O., Simpson-Haidaris P.J. Functional analysis of interleukin 6 response elements (IL-6REs) on the human gammafibrinogen promoter: Binding of hepatic Stat3 correlates negatively with transactivation potential of type II IL-6REs. J. Biol. Chem. 2003; 278: 41270–81. DOI: 10.1074/jbc.M304210200
- Held C., White H.D., Stewart R.A.H., Budaj A., Cannon C.P., Hochman J.S. et al. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. J. Am. Heart Assoc. 2017; 6: e005077. DOI: 10.1161/JAHA.116.005077
- Gulielmos Е., Ryan V.H., Trayhurn P., Hunter L., Morris P.J., German A.J. 11-Hydroxy-β-steroid dehydrogenase gene expression in canine adipose tissue and adipocytes: Stimulation by lipopolysaccharide and tumor necrosis factor α. Dom. An. Endocrin. 2011; 41 (3): 150–61. DOI: 10.1016/j. domaniend.2011.06.001
- Steinberg J.B., Aljure O.D., Fabbro M. Cardiopulmonary bypass and inflammation: the hidden enemy. J. Cardiothorac. Vasc. Anesth. 2019; 33 (2): 346–7. DOI: 10.1053/j.jvca.2018.05.030
- Biffl W.L., Pontes A.S. Efeito da L-aminoácido oxidase isolada do veneno da serpente calloselasma rhodostoma na função de neutrófilos humanos (Doctoral dissertation). 2016.
- Te Winkel J.P., Drucker N.A., Morocho B.S., Shelley W.C., Markel T.A. Interleukin-6 therapy improves intestinal recovery following ischemia. J. Surg. Res. 2019; 239: 142–8. DOI: 10.1016/j.jss.2019.02.001
- Yasuda K., Nakanishi K., Tsutsui H. Interleukin-18 in health and disease. Int. J. Mol. Sci. 2019; 20: 649. DOI: 10.3390/ijms20030649
- Mallat Z., Corbaz A., Scoazec A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001; 104: 1598–603. DOI: 10.1161/hc3901.096721
- Zhang H., Park Y., Wu J., Chen X., Lee S., Yang J. et al. Role of TNF-alpha in vascular dysfunction. Clin. Sci. 2009; 116: 219–30. DOI: 10.1042/CS20080196 16. Zhu M., Lei L., Zhu Z., Li Q., Guo D., Xu J. et al. Excess TNF-alpha in the blood activates monocytes with the potential to directly form cholesteryl ester-laden cells. Acta Biochim. Biophys. Sin. 2015; 47: 899–907. DOI: 10.1093/abbs/gmv092
- Schulze C., Conrad N., Schütz A. Reduced expression of systemic proinflammatory cytokines after off-pump versus conventional coronary artery bypass grafting. Thorac. Cardiovasc. Surg. 2000; 48: 364–9. DOI: 10.1055/s-2000-8352
- Jongman R.M., Zijlstra J.G., Kok W.F., van Harten A.E., Mariani M.A., Moser J. Off-pump CABG surgery reduces systemic inflammation compared with on-pump surgery but does not change systemic endothelial responses: a prospective randomized study. Shock. 2014; 42 (2): 121–8. DOI: 10.1097/SHK.0000000000000190
- Hesse D.G., Shih H.J., Chang C.Y., Chiang M., Le V.L., Hsu H.J., Huang C.J. Simultaneous inhibition of three major cytokines and its therapeutic effects: a peptide-based novel therapy against endotoxemia in mice. J. Personal. Med. 2021; 11 (5): 436. DOI: 10.3390/jpm11050436
- Sproston N.R., & Ashworth J.J. Role of C-reactive protein at sites of inflammation and infection. Fron. Immunol. 2018; 9: 754. DOI: 10.3389/fimmu.2018.00754
- Li H., Sun K., Zhao R., Hu J., Hao Z., Wang F., Zhang Y. Inflammatory biomarkers of coronary heart disease. Front. Biosci. Sch. 2018; 10 (1): 185–96. DOI: 10.2741/s508
- Kosmidou I., Redfors B., Chen S., Crowley A., Lembo N.J., Karmpaliotis D., Stone G.W. C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: analysis from the EXCEL trial. Am. Heart J. 2019; 210: 49–57. DOI: 10.1016/j.ahj.2018.12.013
- Ridker P.M., Bhatt D.L., Pradhan A.D., Glynn R.J., MacFadyen J.G., Nissen S.E. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials. Lancet. 2023; 401 (10384): 1293–301. DOI: 10.1016/S0140-6736(23)00215-5
- Jia R.F., Li L., Li H., Cao X.J., Ruan Y., Meng S., Jin, Z.N. Meta-analysis of C-reactive protein and risk of angina pectoris. Am. J. Cardiol. 2020; 125 (7): 1039–45. DOI: 10.1016/j. amjcard.2020.01.005
- Alzalzalah A. C‐reactive protein as a biomarker of oral health and risk of cardiovascular disease in healthy and CV disease subjects. Baltimore: University of Maryland; 2017. 26. Gupta S., Gupta V.K., Gupta R., Arora S., Gupta V. Relationship of high‐sensitive C‐reactive protein with cardiovascular risk factors, clinical presentation and angiographic profile in patients with acute coronary syndrome: An Indian perspective. Ind. Heart J. 2013; 65 (3): 359–65. DOI: 10.1016/j.ihj.2013.04.035
- Chandrashekara S. C‐reactive protein: An inflammatory marker with specific role in physiology, pathology, and diagnosis. Int. J. Rheumatol. Clin. Immunol. 2014; 2 (S1): 105–21. DOI: 10.15305/ijrci/v2iS1/117
- Elkind M.S.V., Leon V., Moon Y.P., Paik M.C., Sacco R.L. High‐sensitivity C‐reactive protein and lipoprotein‐associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke. 2009; 40 (10): 3233–7. DOI: 10.1161/STROKEAHA.109.552802
- Christiansen M.K. Early-onset coronary artery disease clinical and hereditary aspects. Dan. Med. J. 2017; 64 (9): pii: B5406.
- De Rosa R., Vasa‐Nicotera M., Leistner D.M., Reis S.M., Thome C.E., Boeckel J. Coronary atherosclerotic plaque characteristics and cardiovascular risk factors – Insights from an optical coherence tomography study. Circ. J. 2017; 81: 1165–73. DOI: 10.1253/circj.CJ-17-0054
- Zhong Z.X., Li B., Li C.R., Zhang Q.F., Liu Z.D., Zhang P. Role of chemokines in promoting instability of coronary atherosclerotic plaques and the underlying molecular mechanism. Braz. J. Med. Biol. Res. 2015; 48 (2): 161–6. DOI: 10.1590/1414-431X20144195
- Heo R.H., Wang M.K., Meyre P.B., Birchenough L., Park L., Vuong K. Associations of inflammatory biomarkers with the risk of morbidity and mortality after cardiac surgery: a systematic review and meta-analysis. Can. J. Cardiol. 2023. DOI: 10.1016/j.cjca.2023.07.021
- Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis. 2008; 11 (3): 215–21. DOI: 10.1007/s10456-008-9114-4
- Heeschen C., Dimmeler S., Fichtlscherer S., Hamm C.W., Berger J., Simoons M.L., Zeiher A.M. CAPTURE Investigators. Prognostic value of placental growth factor in patients with acute chest pain. J. Am. Med. Assoc. 2004; 291: 435–41. DOI: 10.1001/jama.291.4.435
- Bui A.H., Bonaca M.P., Sabatine M.S. Elevated concentration of placental growth factor (PlGF) and long term risk in patients with acute coronary syndrome in the PROVE IT-TIMI 22 trial. J. Thromb. Thrombolys. 2012; 34 (2): 222–8. DOI: 10.1007/s11239-012-0704-z
- Zouridakis E., Avanzas P., Arroyo-Espliguero R., Fredericks S., Kaski J.C. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation. 2004; 110 (13): 1747–53. DOI: 10.1161/01.CIR.0000142664.18739.92
- Gupta S., Varol E., Gülcan M., Aylak F., Özaydın, M., Sütçü, R., Erdoğan D. Increased neopterin levels and its association with angiographic variables in patients with slow coronary flow: an observational study. Anatol. J. Cardiol. (Anadol. Kardiyol. Derg.). 2011; 11 (8). DOI: 10.5152/akd.2011.190
- Dominguez-Rodriguez A., Abreu-Gonzalez P., GarciaGonzalez M. Usefulness of neopterin levels and left ventricular function for risk assessment in survivors of acute myocardial infarction. Int. J. Cardiol. 2006; 111 (2): 318–20. DOI: 10.1016/j. ijcard.2005.11.024
- Krantz D., Goetzl L., Simpson J.L. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancyassociated plasma protein-A, and nuchal translucency with intrauterine growth retardation and other adverse pregnancy outcomes. Am. J. Obstet. Gynecol. 2004; 191: 1452–8. DOI: 10.1016/j.ajog.2004.05.068
- Lund J., Qin Q.P., Ilva T. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation. 2003; 108: 1924–6. DOI: 10.1161/01.CIR.0000096054.18485.07
- Li C., Zhong X., Xia W., He J., Gan H., Zhao H. The CX3CL1/CX3CR1 axis is upregulated in chronic kidney disease and contributes to angiotensin II-induced migration of vascular smooth muscle cells. Microvasc. Res. 2020; 132: 104037. DOI: 10.1016/j.mvr.2020.104037
- Boag S.E. T lymphocytes and fractalkine contribute to myocardial ischema reperfusiom injury in patients. J. Clin. Invest. 2015; 125 (8): 3063. DOI: 10.1172/JCI80055
About Authors
- Atabi Sh. Iraskhanov, Postgraduate; ORCID
- Yuriy I. Buziashvili, Dr. Med. Sci., Professor, Academician of the RAS, Head of Department; ORCID
- Inna.V. Koksheneva, Dr. Med. Sci., Senior Researcher; ORCID
- Elvina F. Tugeeva, Dr. Med. Sci., Senior Researcher; ORCID
- Tabarik R. Timerbulatova, Resident Physician; ORCID